1. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients
- Author
-
Eliane C. M. Zeestraten, Peter J. K. Kuppen, Gerrit-Jan Liefers, Marlies S. Reimers, C.J.H. van de Velde, P.J. van den Elsen, J-W T Dekker, S. Saadatmand, Pathology, and CCA - Immuno-pathogenesis
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,HLA-E ,Colorectal cancer ,HLA-G ,Genes, MHC Class I ,Foxp3+regulatory T cells ,clinical outcome ,Human leukocyte antigen ,HLA Class I expression ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Molecular Diagnostics ,HLA-G Antigens ,colon ,business.industry ,immune surveillance ,Histocompatibility Antigens Class I ,Forkhead Transcription Factors ,Middle Aged ,Prognosis ,medicine.disease ,colon cancer ,Colonic Neoplasms ,Immunology ,Female ,Foxp3+ regulatory T cells ,business ,Tumor immunology - Abstract
Background: Evasion of immune surveillance and suppression of the immune system are important hallmarks of tumour development in colon cancer. The goal of this study was to establish a tumour profile based on biomarkers that reflect a tumour's immune susceptibility status and to determine their relation to patient outcome. Methods: The study population consisted of 285 stage I-IV colon cancer patients of which a tissue micro array (TMA) was available. Sections were immunohistochemically stained for the presence of Foxp3+ cells and tumour expression of HLA Class I (HLA-A, -B, -C) and non-classical HLA-E and HLA-G. All markers were combined for further analyses, resulting in three tumour immune phenotypes: strong immune system tumour recognition, intermediate immune system tumour recognition and poor immune system tumour recognition. Results: Loss of HLA class I expression was significantly related to a better OS (P-value 0.005) and DFS (P-value 0.008). Patients with tumours who showed neither HLA class I nor HLA-E or -G expression (phenotype a) had a significant better OS and DFS (P-value
- Published
- 2013
- Full Text
- View/download PDF